
Gilead Sciences
This is our global website, intended for visitors seeking information on Gilead’s worldwide business. Some content on this site is not intended for people outside the United States.
Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information.
Careers at Gilead Sciences
Gilead, a global biopharma co. pursuing innovation in virology, oncology and inflammation, offers a variety of career opportunities in an inclusive workplace where all can make an impact.
Virology, Inflammation, & Oncology Pipeline | Gilead
Oct 30, 2025 · Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, & inflammation. Learn about our pipeline.
Gilead Sciences Medicines
Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology & inflammation.
Gilead Sciences: Career Opportunities
Explore career opportunities and jobs at Gilead Sciences, a biopharma company with an inclusive culture where all employees can help build a healthier world.
Stories - Gilead Sciences
First Deliveries of Gilead's Twice-Yearly HIV Prevention Therapy in Sub-Saharan Africa – and What it Means for Ending the HIV Epidemic November 21, 2025
Gilead Sciences – Leading with world-class science
Fueled by scientific innovation, we’re generating transformative medicines and cures across virology, oncology and inflammation.
Gilead Sciences, Inc. - Investor Relations
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it …
Gilead Sciences Announces First Quarter 2025 Financial Results
Apr 24, 2025 · At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be …